{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T12:54:24Z","timestamp":1776344064669,"version":"3.51.2"},"reference-count":27,"publisher":"Elsevier BV","issue":"10244","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/s0140-6736(20)30748-0","type":"journal-article","created":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T18:33:07Z","timestamp":1590085987000},"page":"121-128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":568,"title":["Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials"],"prefix":"10.1016","volume":"396","author":[{"given":"Muthiah","family":"Vaduganathan","sequence":"first","affiliation":[]},{"given":"Brian L","family":"Claggett","sequence":"additional","affiliation":[]},{"given":"Pardeep S","family":"Jhund","sequence":"additional","affiliation":[]},{"given":"Jonathan W","family":"Cunningham","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o","family":"Pedro Ferreira","sequence":"additional","affiliation":[]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[]},{"given":"Milton","family":"Packer","sequence":"additional","affiliation":[]},{"given":"Gregg C","family":"Fonarow","sequence":"additional","affiliation":[]},{"given":"John J V","family":"McMurray","sequence":"additional","affiliation":[]},{"given":"Scott D","family":"Solomon","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S0140-6736(20)30748-0_bib1","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/j.jacc.2017.08.074","article-title":"Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes","volume":"70","author":"Shah","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/S0140-6736(20)30748-0_bib2","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s11606-012-2072-y","article-title":"The average lifespan of patients discharged from hospital with heart failure","volume":"27","author":"Alter","year":"2012","journal-title":"J Gen Intern Med"},{"key":"10.1016\/S0140-6736(20)30748-0_bib3","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry","volume":"72","author":"Greene","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/S0140-6736(20)30748-0_bib4","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ejhf.1459","article-title":"Physicians' guideline adherence is associated with long-term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry","volume":"21","author":"Komajda","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/S0140-6736(20)30748-0_bib5","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jchf.2018.10.010","article-title":"Contemporary drug treatment of chronic heart failure with reduced ejection fraction: the CHECK-HF registry","volume":"7","author":"Brunner-La Rocca","year":"2019","journal-title":"JACC Hear Fail"},{"key":"10.1016\/S0140-6736(20)30748-0_bib6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(20)30748-0_bib7","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(20)30748-0_bib8","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(20)30748-0_bib9","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(20)30748-0_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchf.2019.12.015","article-title":"Contemporary treatment patterns and clinical outcomes of comorbid diabetes mellitus and HFrEF: the CHAMP-HF registry","author":"Vaduganathan","year":"2020","journal-title":"JACC Heart Fail"},{"key":"10.1016\/S0140-6736(20)30748-0_bib11","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1016\/j.jacc.2019.02.015","article-title":"Longitudinal titration of medical therapy for heart failure with reduced ejection fraction: CHAMP-HF registry","volume":"73","author":"Greene","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/S0140-6736(20)30748-0_bib12","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.jchf.2018.03.006","article-title":"Temporal trends in the incidence of and mortality associated with heart failure with preserved and reduced ejection fraction","volume":"6","author":"Tsao","year":"2018","journal-title":"JACC Heart Fail"},{"key":"10.1016\/S0140-6736(20)30748-0_bib13","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehaa184","article-title":"A putative placebo analysis of the effects of sacubitril\/valsartan in heart failure across the full range of ejection fraction","author":"Vaduganathan","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/S0140-6736(20)30748-0_bib14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1067\/mhj.2001.111262","article-title":"Active-control trials: how would a new agent compare with placebo? A method illustrated with clopidogrel, aspirin, and placebo","volume":"141","author":"Fisher","year":"2001","journal-title":"Am Heart J"},{"key":"10.1016\/S0140-6736(20)30748-0_bib15","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1002\/sim.1454","article-title":"The use of putative placebo in active control trials: two applications in a regulatory setting","volume":"22","author":"Durrleman","year":"2003","journal-title":"Stat Med"},{"key":"10.1016\/S0140-6736(20)30748-0_bib16","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1177\/009286150103500212","article-title":"Statistical methods for comparison to placebo in active-control trials","volume":"35","author":"Hasselblad","year":"2001","journal-title":"Drug Inform J"},{"key":"10.1016\/S0140-6736(20)30748-0_bib17","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1093\/eurheartj\/ehu455","article-title":"A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure","volume":"36","author":"McMurray","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/S0140-6736(20)30748-0_bib18","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMc1509753","article-title":"Estimating the long-term treatment benefits of sacubitril-valsartan","volume":"373","author":"Claggett","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(20)30748-0_bib19","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1016\/j.jacc.2019.02.043","article-title":"Estimated long-term survival with eplerenone","volume":"73","author":"Stienen","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/S0140-6736(20)30748-0_bib20","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.jchf.2019.08.017","article-title":"MRAs in elderly HF patients: individual patient-data meta-analysis of RALES, EMPHASIS-HF, and TOPCAT","volume":"7","author":"Ferreira","year":"2019","journal-title":"JACC Hear Fail"},{"key":"10.1016\/S0140-6736(20)30748-0_bib21","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1093\/eurheartj\/ehv330","article-title":"Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF","volume":"36","author":"Jhund","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/S0140-6736(20)30748-0_bib22","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1161\/CIRCULATIONAHA.119.044133","article-title":"Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to age: insights from DAPA-HF","volume":"141","author":"Martinez","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/S0140-6736(20)30748-0_bib23","article-title":"Thirty years of evidence on the efficacy of drug treatments for chronic heart failure with reduced ejection fraction: a network meta-analysis","volume":"10","author":"Burnett","year":"2017","journal-title":"Circ Hear Fail"},{"key":"10.1016\/S0140-6736(20)30748-0_bib24","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/jamacardio.2016.4733","article-title":"Reduced risk of hyperkalemia during treatment of heart failure with mineralocorticoid receptor antagonists by use of sacubitril\/valsartan compared with enalapril: a secondary analysis of the PARADIGM-HF trial","volume":"2","author":"Desai","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/S0140-6736(20)30748-0_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchf.2018.06.011","article-title":"Initiation, continuation, switching, and withdrawal of heart failure medical therapies during hospitalization","volume":"7","author":"Bhagat","year":"2019","journal-title":"JACC Heart Fail"},{"key":"10.1016\/S0140-6736(20)30748-0_bib26","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cardfail.2013.05.017","article-title":"Expanding the scope of the \u2018polypill\u2019 to heart failure","volume":"19","author":"Vaduganathan","year":"2013","journal-title":"J Card Fail"},{"key":"10.1016\/S0140-6736(20)30748-0_bib27","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2019.11533","article-title":"Communication strategies for sharing prognostic information with patients: beyond survival statistics","volume":"322","author":"Paladino","year":"2019","journal-title":"JAMA"}],"container-title":["The Lancet"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0140673620307480?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0140673620307480?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:19:06Z","timestamp":1758845946000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0140673620307480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":27,"journal-issue":{"issue":"10244","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0140673620307480"],"URL":"https:\/\/doi.org\/10.1016\/s0140-6736(20)30748-0","relation":{},"ISSN":["0140-6736"],"issn-type":[{"value":"0140-6736","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials","name":"articletitle","label":"Article Title"},{"value":"The Lancet","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S0140-6736(20)30748-0","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S0140-6736(20)30929-6","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}